The Metals Company — Entering a pivotal year

The Metals Company (NASDAQ: TMC)

Last close As at 21/12/2024

USD0.73

−0.04 (−5.35%)

Market capitalisation

USD250m

More on this equity

Research: Metals & Mining

The Metals Company — Entering a pivotal year

The Metals Company’s (TMC’s) pioneering journey towards mining polymetallic nodules from the deep sea continues. There are inevitable hurdles to surpass, such as Greenpeace’s recent protests, which were a minor disturbance. With a further funding option now in place the company is well positioned to deliver a crucial milestone, submission of an exploitation application in 2024 as planned.

David Larkam

Written by

David Larkam

Analyst, Industrials

Nickel Refinery covered in dust_ Metal company

Metals & Mining

The Metals Company

Entering a pivotal year

Crucial milestone in FY24

Metals and mining

4 December 2023

Price

$1.18

Market cap

$360m

Net cash at 30 September 2023

$22.5m

Shares in issue

305m

Free float

57%

Code

TMC

Primary exchange

Nasdaq

Share price performance

Business description

The Metals Company is a deep-sea minerals exploration company focused on the collection, processing and refining of polymetallic nodules, containing nickel, copper and cobalt, found on the seafloor in the international waters of the Clarion Clipperton Zone, 1,300 nautical miles off the coast of Southern California.

Analyst

David Larkam

+44 (0)20 3077 5700

The Metals Company is a research client of Edison Investment Research Limited

The Metals Company’s (TMC’s) pioneering journey towards mining polymetallic nodules from the deep sea continues. There are inevitable hurdles to surpass, such as Greenpeace’s recent protests, which were a minor disturbance. With a further funding option now in place the company is well positioned to deliver a crucial milestone, submission of an exploitation application in 2024 as planned.

Year end

Revenue ($m)

PBT*

($m)

EPS*
(c)

DPS
(c)

P/E
(x)

Yield
(%)

12/22

0

(86)

(36)

0

N/A

N/A

12/23e

0

(50)

(18)

0

N/A

N/A

12/24e

0

(50)

(17)

0

N/A

N/A

12/25e

0

(40)

(14)

0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

An additional environmental offshore campaign is underway. Scientists are currently undertaking further studies on the site of last year’s nodule collection system test to gather further environmental data on ecosystem recovery and functioning. This will provide data for the company’s environmental and social impact assessment (ESIA), required for the exploitation contract as well as for the wider understanding of the ecosystem. Greenpeace has been actively discouraging this work, including boarding the vessel on 23 November. Since this time the secretary-general of the International Seabed Authority (ISA) has requested ‘all parties present in the vicinity of NORI’s vessel MV Coco as of 27 November 2023…maintain a safety distance from MV Coco of at least 500m’. Subsequently the District Court of Amsterdam has ordered Greenpeace International to immediately disembark from the research vessel.

TMC’s financial position has been enhanced through a further regulatory filing. The group had cash of $22.5m at 30 September 2023, before $9.2m in additional proceeds from a registered direct offering from ERAS Capital and a $25m unsecured credit facility from an affiliate of Allseas. In addition, TMC has a $30m at-the-market equity programme, which remains untapped, and $19m of warrants outstanding, albeit at $3 a share. This leaves $26m of equity headroom under the existing S-3. A new S-3 filing extends this by a further $100m. The company stated with its Q3 update that a further c $40m of financing was required to complete the current campaign, environmental statements/impact reports and submit an exploitation application. The company continues to review a range of options for such funds. The S-3 filing ensures that the equity markets remain a viable avenue.

The ISA 28th session meeting (Part III) took place in November with the agreement to ‘deliver the consolidated text of the draft exploitation regulations to pursue negotiations in March 2024’. It remains on track to the revised timeline to deliver the mining regulation in July 2024.

There is no change to our valuation from our August update note. 2024 is set to be a pivotal year, with the anticipated adoption of exploitation legislation and TMC’s stated intention to apply for an exploitation contract.

General disclaimer and copyright

This report has been commissioned by The Metals Company and prepared and issued by Edison, in consideration of a fee payable by The Metals Company. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by The Metals Company and prepared and issued by Edison, in consideration of a fee payable by The Metals Company. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on The Metals Company

View All

Metals & Mining

The Metals Company — Growing up

Nickel Refinery covered in dust_ Metal company

Metals & Mining

The Metals Company — Entering a pivotal year

Latest from the Metals & Mining sector

View All Metals & Mining content

Research: Healthcare

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Biodexa has reached an agreement to acquire worldwide rights to Adhera Therapeutics’ Phase II-ready asset, tolimidone, a novel lyn kinase activator, with intentions to develop it for type I diabetes (T1D). The deal consideration includes an upfront cash payment of US$0.3m to Adhera and US$2m in American depository shares (ADS) to Adhera’s secured noteholders with up to US$4m in additional deferred stock consideration to noteholders. These rights have been sub-licensed from Melior Pharmaceuticals, which has been developing tolimidone in type II diabetes (T2D) (Phase II) and non-alcoholic steatohepatitis (Phase I). Unlike T2D, which is a lifestyle disease, T1D is an autoimmune condition (requiring daily insulin treatment) and currently has no curative therapies. We see this deal as diversifying Biodexa’s development pipeline outside oncology and into an area with sizable commercial opportunity (US$7.6bn market).

Continue Reading
Midatech Pharma_resized

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free